When I hear public uproar over the price of prescription drugs, my initial urge is to defend the pharmaceutical companies. The average R&D cost for a new molecular entity (NME) to get from bench to bedside is over $800 million* (cue the Dr. Evil music). It does not help that the FDA charges almost $2 million just to submit a new drug application (NDA) for review. Drug discovery is a pricey business and ...
I’m in the habit of scanning the news throughout the day and bookmarking articles that I don’t have time to read at that moment. Unfortunately, this leads to a bookmarks folder brimming with articles that I may never get to (516 and counting, if you must know). But the long Memorial Day weekend allowed me to make a dent, and I thought I’d share a few of the highlights: NPR recently reported ...
Whether it’s for a potential new client or an existing one, we, as an industry, often try to achieve their business objectives with a laundry list of our products and solutions, or our “capabilities.” We have all seen it and most of us (including me) are guilty of doing this from time to time. Then we leave it up to the client to determine whether or not our solutions and functional capabilities line up with ...